认知障碍预测亨廷顿病的药物差异:患者自我报告与药房记录相比
Stephanie Feleus1,2, Mai-Ly T D Vo3, Laura C M Kuijper4
1Department of Neurology, Leiden University Medical Center, PO 9600, 2300RC, Leiden, The Netherlands. s.feleus@lumc.nl.
Journal of neurology
|December 12, 2024
概括
药物差异在亨廷顿症中很常见.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 药物调和对于患者的安全至关重要,特别是在诸如亨廷顿病 (HD) 等神经退行性疾病中.
- 准确的药物调和可以防止药物相互作用和住院等不良事件.
- 人们对HD患者药物不一致的频率和贡献因素知之甚少.
研究的目的:
- 为了确定与亨廷顿病患者的药物差异相关的预后因素.
- 将患者报告的药物使用与当地药房记录进行比较.
主要方法:
- 一个多变量逻辑回归分析对134名预先和明显的HD患者进行.
- 依赖变量:药物差异 (参考:药房记录).
- 独立变量包括人口统计,疾病状况,药物数量,护理人员的存在以及认知/行为评分.
主要成果:
- 药物治疗的差异很常见:43.2%在预先表现的HD和36.7%在明显的HD.
- 认知障碍是药物差异的重要预测因素 (p=0.011).
- 其他因素,如性别,疾病状况,护理人员的存在和行为评分是无关紧要的.
结论:
- 患者自我报告的药物使用在亨廷顿病中不可靠,特别是在认知障碍的情况下.
- 护理人员的存在,多药,抑郁,焦虑和冷漠没有影响自我报告的准确性.
- 建议在本地药房客观地验证药物使用情况,以帮助HD患者.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
96
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
96
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Parkinson's Disease: Treatment
219
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
219
Dementia
96
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
96


